WASHINGTON — The Food and Drug Administration is undaunted by the fact that many of its top staff are nearing retirement age and the agency has a plan to continue to buttress its ranks, both among the leadership and rank-and-file, Commissioner Scott Gottlieb said Friday.

“It is the case that about 50 percent of all the people in senior roles in [the Center for Drug Evaluation and Research] right now are nearing retirement age, where they can retire with benefits,” Gottlieb said. “We’ve been aware of that. We’ve been planning for it.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Mr. Gottlieb. What a story? Can someone please check HUGE MESS in DENTAL Medical devices. FDA published on the Internet documents from late 90 retaping with and added stamp. I send a month ago info about this to his attention. Now he tried to send people who was part of the scam on retiremet. My case is in court against big dental lab Nobel Biocare. I never see scam presented to the public in the form FDA did. After almost 2 years after I was hurt I checked dental medical devices record 510(k) and send information to criminal investigation to fda. They didn’t respond for months.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy